Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is an aggressive pediatric malignancy of the muscle, that includes Fusion Positive (FP)-RMS harboring PAX3/7-FOXO1 and Fusion Negative (FN)-RMS commonly with RAS pathway mutations. RMS express myogenic master transcription factors MYOD and MYOG yet are unable to terminally differentiate. Here, we report that SNAI2 is highly expressed in FN-RMS, is oncogenic, blocks myogenic differentiation, and promotes growth. MYOD activates SNAI2 transcription via super enhancers with striped 3D contact architecture. Genome wide chromatin binding analysis demonstrates that SNAI2 preferentially binds enhancer elements and competes with MYOD at a subset of myogenic enhancers required for terminal differentiation. SNAI2 also suppresses expression of a muscle differentiation program modulated by MYOG, MEF2, and CDKN1A. Further, RAS/MEK-signaling modulates SNAI2 levels and binding to chromatin, suggesting that the differentiation blockade by oncogenic RAS is mediated in part by SNAI2. Thus, an interplay between SNAI2, MYOD, and RAS prevents myogenic differentiation and promotes tumorigenesis. Rhabdomyosarcomas are tumours blocked in myogenic differentiation, which despite the expression of master muscle regulatory factors, including MYOD, are unable to differentiate. Here, the authors show that SNAI2 is upregulated by MYOD through super enhancers, binds to MYOD target enhancers, and arrests differentiation.

R habdomyosarcoma (RMS) is a pediatric malignancy of the muscle that accounts for 50% of all soft tissue sarcomas in childhood and 7-8% of all pediatric cancers. RMS is best described as a tumor of skeletal muscle lineage blocked in various stages of differentiation. The two common histological subtypes, Alveolar or Embryonal RMS, are now molecularly defined by the presence (Fusion Positive; FP-RMS) or absence (Fusion Negative; FN-RMS) of PAX3/7-fusion genes respectivley 1,2 . In FP-RMS, the most common lesion is the PAX3/7-FOXO1 gene fusion, while FN-RMS most frequently harbor RAS pathway mutations 3,4 . Current multimodal therapy includes a combination of surgery, radiotherapy, and chemotherapy 5,6 ; but despite this, the survival rate in metastatic refractory RMS is less than 30% 7,8 . Therefore, there is a need to better understand the molecular underpinnings of RMS, to develop novel therapies, and reduce toxicity thereby improving morbidity and mortality due to this aggressive disease.
RMS cells robustly express the myogenic transcription factors MYOD and MYOG, but yet are unable to terminally differentiate. Competition between MYOD and HEY1, TWIST1 and spliceforms of co-factor E2A have been shown to interfere with MYOD transcriptional activity and block terminal differentiation, however, this does not explain how MYOD is able to drive early myogenic gene expression (MYOG), yet unable to mediate terminal differentiation [9][10][11] .
In this study, we show that SNAI2, a member of the SNAIL family of transcriptional factors, is highly expressed in FN-RMS and acts as an oncogene through selective inhibition of MYODdriven differentiation and by down-regulating multiple transcription factors necessary for terminal differentiation, thereby blocking myogenic differentiation and supporting growth. These effects cannot be solely ascribed to SNAI2 functions in the epithelial to mesenchymal transition 12 , but rather to fundamental effects on muscle biology. SNAI2 is known to repress the transcription of target genes by specifically binding the consensus motif CANNTG (i.e., E-box), and there are only a few reports characterizing genome-wide SNAI2 binding but none in RMS [13][14][15] . Here we report that SNAI2 directly represses the expression of MYOD bound differentiation genes, including MYOG, MEF2A, and TNNI1, by binding to E-box motifs mostly at genic enhancers. We define several critical aspects of SNAI2 functioning as an oncogene in FN-RMS. First, we define the SNAI2 regulatory locus and identify MYOD as a direct regulator of SNAI2 expression. Second, we connect mechanistically the cellular and molecular effects of SNAI2 on blocking tumor differentiation and promoting growth. Additionally, we show that combining SNAI2 reduction with standard of care vincristine results in synergistic reduction in tumor volume and robust enhancement of muscle differentiation. Lastly, we report convergent transcriptional consequences from either inhibition of mutant RAS signaling or depletion of SNAI2, suggesting a functional link between SNAI2 and the RAS pathway in FN-RMS.

Results
SNAI2 is highly expressed in RMS and is regulated by MYOD bound super enhancers. We first investigated expression of SNAI2 and found it is up-regulated in tumor samples and cell lines compared to normal tissue with FN-RMS having higher expression by RNA-seq analysis (>4log 2 FPKM) (Fig. 1a) 4 . In RMS cell lines the higher mRNA expression was associated with higher SNAI2 protein levels when compared to primary human myoblasts (Fig. 1b). Of note, SNAI2 is located on chromosome 8 which is gained in two thirds of all RMS tumors 4 . Analysis of SNAI2 expression in a different cohort of approximately 2000 pediatric cancers from the St. Jude-PeCan portal confirmed that SNAI2 is highly expressed in RMS tumors and, especially, FN-RMS compared to other pediatric cancers with only osteosarcoma tumors expressing higher SNAI2 (Fig. S1a). Immunohistochemical staining also revealed high protein expression of SNAI2 in 14 of 19 FN-RMS and 3 of 4 FP-RMS pediatric primary tumors ( Fig. 1c and Fig. S1b).
Tumor-type or cell-type selective expression of a gene is controlled often by nearby super enhancers (SEs) that are only active in the relevant cellular state 16 . To establish the genomic loci within which SNAI2 enhancers may exist, we defined the tridimensional structure around the SNAI2 locus by analyzing Hi-C data reported for human lung fibroblasts 17 and found a "stripe" pattern 18 of 1.2 Mb within a topologically associated domain (TAD) containing SNAI2 (Fig. 1d), indicating high levels of interactions, and spatial organization. Multiple active enhancers and SEs were discovered within this SNAI2 TAD using the H3K27ac mark in a set of 11 FP-RMS (6 cell lines and 5 primary tumors) and 9 FN-RMS (5 cell lines and 4 primary tumors) 19 (Fig. 1e). Many active SEs in human skeletal myoblasts strongly overlap with RMS SEs (both in FP-RMS and FN-RMS), which are reduced during differentiation 19 . Similarly, we find that the SNAI2 SEs that are maintained in RMS are among those that decrease during myogenesis and are mostly absent in fully mature muscle (Fig. 1e).
The higher expression of SNAI2 compared to normal tissues and its expression in a majority of RMS samples suggested potential control by master regulators known to be shared between both FP-RMS and FN-RMS 19,20 . Myod through binding to a proximal promoter region can regulate Snai2 expression during muscle regeneration and in the early phase of differentiation in murine myoblasts 21 . To further investigate the transcriptional regulation of SNAI2 by MYOD in FN-RMS, we first used ChIP-seq to assess MYOD binding in mutant RAS-driven FN-RMS cells (SMS-CTR and RD) 22,23 . We found that the SNAI2 cisregulatory environment is bound by MYOD in active chromatin (H3K27ac), not only at the proximal promoter but also at distal enhancer and SE sites (Fig. 1f). Examining the same sites in myoblasts and myotubes revealed that MYOD and H3K27ac are present but decrease at SNAI2 sites during muscle differentiation (Fig. 1f). To evaluate the chromatin conformation around the SNAI2 locus in FN-RMS, we performed HiChIP in SMS-CTR cells (Fig. 1g). We confirmed that in FN-RMS SNAI2 regulatory regions interact along a "stripe" that includes the super enhancers E1-E3. Expression analysis of MYOD1 and SNAI2 revealed a significant positive correlation in RMS and normal muscle but not in non-muscle tissues (FN-RMS: Pearson 0.428, p = 0.0000038; FP-RMS: Pearson 0.372, p = 0.0001; Muscle: Pearson 0.494, p = 0.001; Other: Pearson 0.051, p = 0.477) (Fig. S1c). These observations led us to investigate if SNAI2 expression depends on MYOD in FN-RMS. Utilizing short interference RNA (siRNA) knockdown of MYOD, we assessed SNAI2 expression in three FN-RMS cell lines (RD, JR1, and SMS-CTR). We found that MYOD knockdown in all three cell lines suppressed SNAI2 expression at both protein and mRNA levels at 24 and 48 h posttransfection ( Fig. 1h and Fig. S1d). Conversely, when MYOD is ectopically expressed in human mesenchymal-derived fibroblasts lacking MYOD, SNAI2 expression is up-regulated 24 (Fig. S1e). Analysis of a published model of MYOD1 induction by PAX3-FOXO1 in fibroblasts 19 (Fig. S1f, upper) revealed a focused increase of H3K27ac at MYOD sites corresponding to those in SMS-CTR cells on the SNAI2 locus, along with an increase in SNAI2 expression (Fig. S1f, lower).
To test the direct requirement of MYOD binding sites to regulate SNAI2, we performed CRISPRi via dCas9-KRAB recruited to MYOD motifs on the SNAI2 locus in SMS-CTR cells (Fig. 1i). After 72 h of guide RNA mediated repression of 5 candidate regions (E1-E5), we find that SNAI2 transcription was strongly dependent on two binding sites with the highest MYOD deposits (E1 and E2) but not on the more distant sites (E3-E5) with the lowest MYOD signal (Fig. 1i).
While FP-RMS and FN-RMS had similar enhancer structure surrounding SNAI2 and transcriptomic levels of SNAI2, there is a selective dependency for SNAI2 among FN-RMS cells when compared to a panel of cancer cell lines in genome-wide CRISPR screening data from the Achilles Project (Fig. S1g, h).Together our data provide evidence that SNAI2 is expressed in RMS, is regulated by a 1.2 Mb regulatory locus to which muscle-specific transcription factor MYOD can bind to maintain its expression and there is a dependency for SNAI2 in FN-RMS cells.
Suppression of SNAI2 activates myogenic differentiation and suppresses stemness in vitro in FN-RMS. To define the role of SNAI2 in FN-RMS differentiation, we abrogated SNAI2 expression in FN-RMS using lentiviral vectors expressing short hairpin RNAs (shRNA) 25 . These resulted in 58-87% reduction of SNAI2 levels in shRNA-treated RD cells compared to scramble (Scr) (Fig. 2a). RD cells with stable SNAI2 knockdown (KD) when cultured in differentiation medium (DM; supplemented with 2% horse serum) for 3 days, showed a significant increase in differentiation, as assessed by morphology changes leading to elongated myofiber-like structures, de novo expression of the terminal muscle differentiation marker Myosin Heavy Chain 1 (MyHC) and up-regulation of MEF2C ( Fig. 2b-d) compared to scramble shRNA controls. The percentage of MyHC positive cells were~20-fold higher in shSNAI2.1 and~8-fold higher in shSNAI2.2 cells compared to scramble shRNA cells (1.19% ± 0.41 for shScr vs 20.75% ± 2.39 for shSNAI2.1, and 11.33% ± 1.51 for shSNAI2.2) (Fig. 2d). Similar results were obtained in JR1 and SMS-CTR cells ( Fig. S2a-d, i-l). Consistent with increased expression of MyHC-positive cells, real time qRT-PCR analysis in RD cells revealed that SNAI2 KD cells expressed reduced levels of PAX7, a marker of undifferentiated satellite muscle stem cells, and an increase in myogenic regulators MYOD1, MYOG, MEF2C, CDKN1A (p21), MEF2D, and MHCb (MyHC) (Fig. 2e and Fig. S2e). Importantly, while most myogenic transcription factors went up between 1.3 and 6-fold, differentiation marker MyHC expression increased by log folds in RD (Fig. 2e). Similar trends were observed in JR1 and SMS-CTR cells (Fig. S2e, m).
We next assessed the effect of SNAI2 knockdown in vivo, employing RD, JR1, and SMS-CTR cells with scramble shRNA and SNAI2 shRNA xenografted subcutaneously in SCID mice. SNAI2 KD caused a significant reduction in the tumor size, weight and volume compared to control shScr. Indeed, by day 76 RD shSNAI2 tumors were significantly smaller in volume compared to Scr-transduced tumors in the same mice (Fig. 3f), and reduced size and weight compared to scramble shRNA tumors at the experimental end point (Fig. 3g- Hematoxylin and eosin (H&E) staining of the tumors revealed that the SNAI2 knockdown tumors were less dense (Fig. 3j, k and Figs. S4n, o and S5j, k) and more differentiated, as evidenced by increased MyHC staining (percentage of MyHC-stained cells/ field, shScr 3.7 ± 2.4 vs shSNAI2.2 10.7 ± 3.9, p = 0.0003; Student's two-tailed t-test) (Fig. 3l, m and Figs. S4p, q and S5l, m). Altogether, these results strongly support a role for SNAI2 on tumor growth and as a potent suppressor of myogenic differentiation in FN-RMS.
Since SNAI2 KD cells express higher levels of myogenic differentiation transcription factors MYOD, MYOG, and MEF2C, we hypothesized that combining SNAI2 silencing with a standard of care drug in RMS therapy would enhance differentiation of . i Targeted disruption of MYOD binding sites in enhancers surrounding the SNAI2 gene in SMS-CTR cells, using sgRNAs to deliver dCas9-KRAB suppressor. Location of enhancers E1-E5 are shown above. Schematic of experimental workflow shown in bottom left. Bar chart of qRT-PCR measurements for SNAI2 expression after dCas9-KRAB perturbation with various guides is shown in the bottom right; p values shown were calculated among biological triplicates using t-test with Welch's correction. Error bars represent the SD among the 3 biologically independent replicates.
tumor cells often detected as nests of cells after conventional therapy 27 . Therefore, we performed xenograft transplants of Scr and SNAI2 shRNA knockdown cells into SCID mice and once tumors were palpable, mice were treated with a subtherapeutic dose of vincristine (0.5 mg/kg) once a week for 3 weeks 28 and the regrowth of tumor after the end of drug treatment was assessed. We observed that while tumors from both Scr and SNAI2 shRNA treated cells initially decreased in volume, shScr tumors very quickly regrew (Fig. 3n-q and Fig. S4r, s). However, SNAI2 knockdown tumors were unable to grow back quickly and were significantly reduced in volume ( Fig. 3n-q and Fig. S4r, s). This reduction in volume was much more significant than in untreated xenograft experiments. To assess the effect of vincristine on differentiation, a subset of shScr and SNAI2 shRNA-tumor burdened mice were given a single dose of the drug and animals were euthanized and tumors harvested 24 h later and processed for H&E and IHC staining for differentiated myosin (MyHC). H&E staining on SNAI2 knockdown tumors showed features associated with differentiating myoblasts when compared to scramble treated tumors indicating an increase in differentiation (Fig. 3r, s). The effect on MyHC expression was more extreme in shSNAI2.2 cells, which had~15-fold increase in differentiation than control-treated tumors (Fig. 3t, u) (shScr vs shSNAI2.2 2.8 ± 0.8% vs 41.0 ± 2.9% of MyHC stained cells/field, p = 0.00003; Student's two-tailed t-test). These findings support the evidence that SNAI2 is a potent inhibitor of differentiation in vivo. Moreover, SNAI2 knockdown cells are poised towards differentiation, and in this context, treatment with vincristine can synergistically enhance differentiation and exit of tumor cells from the cell cycle resulting in significant reduction in tumor growth.
SNAI2 binds key enhancers in FN-RMS. Our evidence that SNAI2 KD induces differentiation in FN-RMS, combined with the knowledge that Snail proteins can bind to E-box motifs and are rapidly switched-off during normal muscle differentiation 29 , led us to hypothesize that SNAI2, by binding to key sites across the RMS epigenome, arrests myogenic differentiation. To explore this, we mapped the genome-wide profile of SNAI2 chromatin binding, using chromatin immunoprecipitation followed by sequencing (ChIP-seq). To identify high-confidence SNAI2 sites, we performed ChIP-seq in three FN-RMS cell lines, SMS-CTR, RD and JR1. We identified 1069 peaks shared among at least 2 cell lines that included 146 peaks common to all the 3 cell lines (Fig. S6a), and these showed the strongest signal per peak, as exemplified on the regulatory regions of the myogenic gene RYR1 (Fig. 4a). SNAI2-bound loci contained the SNAI2 DNA binding motif (p = 1e-700, HOMER motif analysis) 30 ; however, SNAI2 was also enriched in E-box motifs for known basic helix-loophelix (bHLH) myogenic transcription factors such as MYOD, MYOG, and MYF5 (Fig. 4b), indicating potential co-binding or adjacent binding to myogenic TFs.
To determine the types of chromatin occupied by SNAI2, we used patterns of histone marks and CTCF in SMS-CTR cells 19 to define chromatin states with ChromHMM 31 . SNAI2 associated primarily with the strong enhancer chromatin state in FN-RMS, characterized by H3K27ac and H3K4me1/2 histone modifications, and secondarily to poised promoters (Fig. 4c). Because SNAI2 binds to E-box motifs that share similar chromatin localization pattern with MYOD 20 , we investigated the overlap of SNAI2 and MYOD genome-wide binding in SMS-CTR, RD, and JR1. We defined unique SNAI2 (405, blue), unique MYOD (6689, green), and SNAI2-MYOD overlapping (664, olive) peaks (Fig. 4d). The shared peaks showed the highest SNAI2 and MYOD average signals compared to SNAI2 and MYOD unique peaks (Fig. 4d). Motif analysis of the SNAI2 and MYOD unique (only) and the overlapping peaks revealed highly enriched motifs for known myogenic transcription factors including MYF5 and MYOG in all three groups (Fig. S6b). We found low abundance of the SNAI2 motif in MYOD-only peaks as well as low enrichment of the MYOD motif in SNAI2-only peaks (Fig. S6b). Next, based on chromatin-state association profile, we mapped SNAI2 and MYOD occupancy at enhancer sites. Using the ROSE2 (Rank Order of Super Enhancers) algorithm, we classified the enhancers into typical (n = 8223) and super (n = 516, SEs) (Fig. S6c). SNAI2 localizes at SE regions only at MYOD peaks, owing to the ubiquitous presence of MYOD in SEs, while only a few typical enhancers had SNAI2 alone.
Functional annotation of the MYOD and SNAI2 targets 32 revealed few MYOD-specific or SNAI2-specific processes, while most are common and indicate a strong association with musclespecific processes (Fig. S6d). A large category of genes are involved in MAP kinase activity cascade, a pathway in RASdriven FN-RMS known to block myogenesis 20 . Thus, SNAI2 preferentially binds chromatin associated with enhancers through a repertoire of E-box motifs including the known SNAI2 motif, and the majority of SNAI2 binding is shared with MYOD.
In order to define whether MYOD and SNAI2 co-occupy chromatin spatially, as evidenced by ChIP-seq, and also cotemporally, we performed tandem chromatin immunoprecipitation (re-ChIP) for MYOD followed by SNAI2, and vice versa, at MYOG associated promoter and super enhancers in SMS-CTR cells. Re-ChIP qPCR signal at regions bound by both MYOD and SNAI2 (MYOG SE1 and SE2) revealed strong enrichment irrespective of ChIP order (Fig. 4e). This signal is absent at MYOD-only (MYOG promoter) and SNAI2-only (MRPL9) binding sites. Thus, MYOD and SNAI2 are co-present at key regulatory chromatin locations of MYOG at the same time regulating its expression, possibly through forming a transcriptional condensate or a high-order complex at these regulatory elements.
Ablation of SNAI2 enables MYOD to activate myogenic target genes. Given that SNAI2 binding overlaps with super enhancers and enhancers through E-boxes associated with MYOD, we hypothesized that SNAI2 could be hindering MYOD from fully binding to key myogenic enhancers, thus preventing differentiation in FN-RMS. To investigate this, we performed ChIP-seq for SNAI2 and MYOD in control (scramble shRNA) and SNAI2 knockdown conditions in SMS-CTR and RD cells. shRNA knockdown resulted in reduction of SNAI2 at its cognate sites (Fig. 5a, b). Genome-wide assessment of MYOD occupancy revealed that MYOD deposition did not change overall at either promoters, regular enhancers or SEs (Fig. S7a). However, we found that MYOD deposition specifically increased upon SNAI2 knockdown at peaks overlapping SNAI2 ( Fig. 5c and Fig. S7a, b). We therefore sought to define the identity and consequences on expression of the subset of genes regulated by E-boxes at which SNAI2 competes with MYOD for binding.
Previously, assessing the expression of critical myogenic regulators including MYOD1, MYOG, MCAD, MEF2C, MEF2D, and CDKN1A (Fig. 2e) we demonstrated that SNAI2 blocks expression of genes essential for myogenic differentiation. To more comprehensively and in an unbiased manner connect chromatin-binding events with all possible SNAI2-driven transcriptional changes, we next performed RNA-seq together with gene set enrichment analysis (GSEA) upon SNAI2 knockdown in SMS-CTR and RD cells. The most significantly enriched pathways (FDR q = 0) were Hallmark myogenesis genes, including genes up-regulated during in vitro differentiation from myoblast to myotubes and genes driven by MYOG-activated SEs during FN-RMS treatment with trametinib 20 (Fig. 5d). Conversely, the analysis showed negative enrichment for genes down-regulated during myoblast differentiation ( Fig. 5d and Fig. S7c).
While many myogenic genes are up-regulated after SNAI2 knockdown, these likely represent a mixture of genes both directly repressed by SNAI2 and others indirectly activated, perhaps downstream of a direct SNAI2 target that becomes active. To clarify this, we integrated genomic binding data with Fig. 3 Suppression of SNAI2 reduces tumorigenicity and growth, and induces muscle differentiation in vitro and in vivo in FN-RMS. a Growth curve analysis of RD cells 3 days post puromycin selection after lentiviral infection with shScr or shSNAI2 shRNAs (n = 3 biologically independent experiments, data presented as mean values ± SD, Student's two-tailed t-test, exact p values are reported in the figure). b, c Single cell colony formation assay in RD cells containing shScr or shSNAI2 knockdown and quantitation values of colony forming units (n = 3 biologically independent experiments, data presented as mean values ± SD, Student's two-tailed t-test, exact p values are reported in the figure). d, e Soft agar colony formation assay comparing RD shScr to shSNAI2 infected cells and quantification of colony numbers in wells (n = 3 biologically independent experiments, data presented as mean values ± SD, Student's two-tailed t-test, exact p values are reported in the figure). f RD cells xenografted subcutaneously in mice with shScr (left) or shSNAI2 (right) and followed for 76 days (3 representative mice of 6 shScr, 3 shSNAI2.1, and 3 shSNAI2.2 tumors each, 1 × 10 6 cells). g Tumor volume of mice injected with either shScr or shSNAI2 cells assessed weekly by caliper measurement represented as mm 3 (n = 6 shScr, n = 3 shSNAI2.1, and n = 3 shSNAI2.2 biologically independent experiments, data presented as mean values ± SD, Student's two-tailed t-test, exact p values are reported in the figure). transcriptional data. We matched high-confidence SNAI2 peaks in FN-RMS cell lines (n = 1069, see Fig. S6a) with all candidate target genes in the RNA-seq data, constrained to genes within each SNAI2-containing TAD (predicted by Hi-C data 17 ). We considered myogenic genes that were consistently up-regulated in both RD and SMS-CTR (n = 128). We found 29 high-confidence SNAI2 myogenic directly suppressed genes ( Fig. 5e and Supplementary Table 1) including MYOG, MEF2A, and RASSF4 as well as indirect targets (n = 99) that lack a SNAI2 peak anywhere within their TAD. Indirect targets include muscle differentiation transcription factors MEF2C, CDKN1A, and RB1. The positive regulation of most of these genes has been already associated with a terminal differentiation program in muscle and in RMS, and are activated directly by MYOG via super enhancers 20,29,33 , suggesting MYOG (a direct SNAI2 target) mediates the activation of these indirect targets once up-regulated by SNAI2 knockdown. Interestingly, SNAI2 binds to myogenic enhancers with MYOD at MYOG, MYBPH, TNNT1/2, MAP-KAPK2, and MEF2A, which are all activated during shSNAI2induced differentiation in FN-RMS ( Fig. 5f and Fig. S7d). We looked at MYOG and MEF2A and found they each have enhancers that are proximal in 3D (assessed by H3K27ac HiChIP in SMS-CTR cells, Fig. 5f) that are bound by SNAI2. Once SNAI2 is diminished upon knockdown, focused growth of MYOD binding occurs at these sites of SNAI2 loss (Fig. 5f) and the expression of these genes are robustly activated (the MYOG  enhancer for example, Fig. 5f). Taken together, our data indicate that SNAI2 through competition with MYOD directly blocks terminal differentiation. Additionally, through indirect mechanisms, SNAI2 also inhibits the expression of MEF2C and CDKN1A that are normally repressed in FN-RMS.
MEK inhibitor trametinib induces differentiation in RAS-mutated FN-RMS through unlocking the expression of pro-differentiation myogenic transcription factors 20 . Due to the importance of RAS as an oncogenic driver in FN-RMS, we sought to evaluate if the effects of SNAI2 on differentiation, in the same tumor context, involved the RAF-MEK-ERK pathway. We determined the expression of myogenic genes identified here as direct SNAI2 targets and found that these genes are also up-regulated upon trametinib treatment (shSNAI2 vs shScr: p = 0.0001, trametinib vs DMSO: p = 0.0001; Student's two-tailed t-test) (Fig. 6j).
RAS signal inhibition causes both myogenic SE genes to be activated via MYOG upregulation, but also shuts down RASdependent SEs at negative signal regulation genes 20 . We found that for MYOG-activated SE genes 20 that were altered by knockdown of SNAI2, their expression strongly correlated with those altered by chemical inhibition of the RAS pathway by the MEK inhibitor trametinib (Fig. 6k upper, for MYOG-activated SE genes: Pearson 0.636, p ≤ 0.0001). A similar phenomenon was seen for RAS-dependent SE genes albeit with less significance 20 (Fig. 6k lower, for RAS-dependent SE genes: Pearson 0.1786, p = 0.0087). Our data indicate that SNAI2 KD phenocopies trametinib-induced differentiation.
We next asked, could trametinib be achieving its up-regulation of myogenic targets through SNAI2 function impairment? To address this, we performed ChIP-seq of SNAI2 after trametinib treatment and focused our attention on myogenic enhancers bound by SNAI2 (reported in Fig. 5f). ChIP-seq profiles showed that SNAI2 binding to chromatin was reduced by the MEKi, corresponding to trametinib-induced increase in MYOD binding, H3K27ac abundance, and expression of MYOG, MYBPH, TNNT1, and MEF2A (Fig. 6l). These effects are all seen during shSNAI2-induced differentiation in FN-RMS (Fig. 6m). Moreover, treatment of FN-RMS RD, JR1, and SMS-CTR cells with trametinib results in downregulation of SNAI2 expression by 72 h associated with a loss of phosphorylated ERK1/2 with no effects on total ERK expression (Fig. 6n). Similar to SNAI2-silenced cells, trametinib treated cells also show increased expression of MEF2C (Fig. 6n). Collectively, these results led us to a model where either MEK inhibition or shSNAI2 phenocopy one another through activation of MYOG and a MEF2-program that induces myogenic differentiation; this convergence is evidenced by the prevention of muscle differentiation by shSNAI2 by silencing of MYOG or MEF2A (Fig. 6o).

Discussion
In this study, we report that SNAI2 acts as a bona fide oncogene in FN-RMS with several lines of evidence. Firstly, SNAI2 is highly expressed in FN-RMS tumors compared to normal muscle and the majority of other cancers. Secondly, FN-RMS cells show the most dependency for SNAI2 compared to all other tumor cell lines, including FP-RMS, in the Broad Achilles CRISPR/ Cas9 screen for core dependencies. Additionally, we find that knockdown of SNAI2 results in a robust induction of the myogenic master transcription factors MYOD1 and MYOG with increase in structural muscle genes and in the potent cyclindependent kinase inhibitor CDKN1A. This is accompanied by reduced stemness, tumorigenicity, and growth together with evidence of muscle differentiation both in vivo and in vitro.
We dissect SNAI2-dependent mechanisms in the context of FN-RMS and the muscle differentiation pathway. We report that SNAI2 acts through a gene regulatory network in which its expression is modulated by muscle-lineage master transcription factor MYOD and in turn SNAI2 regulates both MYODdependent and MYOD-independent programs governing cell differentiation and growth.
We find that SNAI2 expression is modulated by a large 1.2 Mb regulatory TAD region, where binding of the enhancer mark H3K27ac is correlated with expression of SNAI2. In development, normal myoblasts show high enhancer activity in this region associated with high expression of SNAI2, which is switched-off in differentiating myotubes and in terminally differentiated muscle. Further, while many pathways and genes are known to regulate SNAI2 in different cell types and tumors 34 , in FN-RMS tumors we find that MYOD can also bind to SNAI2 enhancers and can directly up-regulate its expression. This is especially interesting as it has been previously shown that FN-RMS tumors robustly express MYOD and are dependent on MYOD function for tumorigenesis 35 .
A critical finding of our study is that SNAI2 binding to chromatin is directly linked to differential gene expression and consequently cellular function. Combining ChIP-seq and RNA-seq datasets for SNAI2 and MYOD finds that SNAI2 binds a repertoire of E-box DNA elements, including the SNAI2 E-box and Ebox motifs to which MYOD, MYOG, and MYF5 are known to bind. Importantly, SNAI2 engaged cis-regulatory elements are specifically associated with super enhancers. In the context of FN-RMS, many of the enhancers that SNAI2 engages are associated with myogenic differentiation genes where the binding of SNAI2 competes with that of MYOD. Thus, the repressor function of SNAI2, through selective competition with transcriptional activator function of MYOD, results in enhancer dampening at loci regulating genes driving early muscle differentiation (for example, MYOG and MEF2A) and terminal differentiation genes (for SNAI2 expression in FN-RMS is regulated by MYOD and SNAI2 binding is able to dampen MYOD binding at myogenic transcription factor genes, which contributes to maintenance of a myogenic differentiation block (left). MEK inhibition with trametinib and/or SNAI2 knockdown in FN-RMS releases SNAI2, allowing MYOD to activate genes important for myogenic differentiation (MYOG, MEFs, TNNTs) thus inducing muscle differentiation (middle). Silencing of myogenic SNAI2 target genes (like MYOG or MEF2A) blocks differentiation downstream of SNAI2. Bubbles depict transcriptional co-activators in inactive (gray) or active (yellow) status. example, MYBPH). Our data can explain why MYOD that is robustly expressed and diagnostic of FN-RMS tumors, can modulate early tumor myoblast-like proliferation but is unable to initiate late myotube-like gene expression that would result in exit from the cell cycle and terminal differentiation when SNAI2 is expressed. However, once SNAI2 expression is extinguished, MYOD can quickly occupy these enhancer elements and along with MEF2A/C/D, MYOG, and CDKN1A drive robust expression of multiple terminal myogenic structural proteins. Both MEF2 and p21 Cip1 (CDKN1A) which unlike MYOD or MYOG are poorly expressed in FN-RMS cells 36,37 when activated together with MYOD and MYOG inhibit tumor growth by driving a terminal differentiation program 38,39 . Our results are consistent with and expand the findings in murine myoblasts using an overexpression analysis of Snai1 binding to demonstrate that during early myogenesis, MYOD is unable to bind muscle differentiation genes with canonical G/C-rich binding sites (E-boxes) that are associated with differentiated genes since they are potentially occupied by Snai1 29 . We previously explored the role of SNAI1 in FN-RMS and while we find overall similar effects on sphere formation, the differentiation effects we observed were not as prominent as SNAI2 knockdown, but more importantly we found that SNAI1 regulates only MEF2C, with relatively no effect on MEF2A/D 40 . Conversely, SNAI2 represses MEF2A/C and D expression, suggesting mechanistic differences in the roles of SNAI1 and SNAI2 with respect to FN-RMS differentiation. Thus, our study defines endogenous SNAI2 chromatin binding, currently a challenge in the field, and provides several unique insights on function that are likely to be relevant beyond RMS. Further, since many tissue-specific transcription factors bind Ebox elements, and SNAI2 has the ability to bind a wide repertoire of them, albeit with different affinities, understanding the extent to which similar competition with SNAI2 occurs may potentially determine differentiation state/gene expression in other tissues and or tumors.
MYOD function can also be disrupted by competition for functional E2A co-factor with non-functional E2A splice variants and other expressed factors including TWIST1, TWIST2, and HEY1 9,10,23,41 . However, in the case of TWIST1 and HEY1 this disruption occurs by competition for co-factor E2A and not at the chromatin level 11,22 . Recently, using an inducible over-expression system in a Twist2 positive (Tw2 +) myoblast cell line, Li et al. 41 , showed that Twist2 can activate Snai2 expression, and can compete with all MYOD binding at E-boxes elements generally inhibiting myogenic gene expression. This report also suggests that Twist2 can influence accessibility to chromatin 41 .TWIST2 that is gained in RMS 41 might be another gene in addition to MYOD that can regulate SNAI2. However, while Twist2 appears to generally inhibit myogenesis, our data indicate that SNAI2 downstream of MYOD and RAS/ERK signaling is likely responsible for selective repression of terminal differentiation gene expression through competition with MYOD binding and repression of a MYOG, MEF2, and CDKN1A differentiation program. Further, the involvement of SNAI2 downstream of RAS/ERK signaling, a driver of FN-RMS, could explain the high dependency of this RMS subtype on SNAI2.
In summary, our study identifies SNAI2 as a core oncogene that blocks terminal differentiation and promotes growth and self-renewal in FN-RMS. SNAI2 regulates the transcriptional output of MYOD and myogenic terminal differentiation regulators MYOG, MEF2A/C/ D, and CDKN1A. Moreover, as SNAI2 depletion mimics blockade of the mutant RAS signal (both at the transcriptional level and phenotypic differentiation level), we propose that SNAI2 connects the genetic and epigenetic drivers of FN-RMS. Finally, our results highlight the importance of SNAIL transcription factors for lineage commitment choices made at the enhancer interface. Gene expression. Total RNA from cells was isolated using Qiagen RNA easy kit and cDNA synthesis was performed using High Capacity cDNA Synthesis Kit (ThermoFisher #4368814), quantitative real time PCR was performed on ABI QuantStudio6 Real-Time PCR system. List of PCR primers used in this study is listed in Supplementary Table 2. Fold change gene expression was calculated by ΔΔ ct method. Significance was calculated by Student's two-tailed t-test. Triplicate assays were carried out in three independent experiments.
Western blotting. Total cell lysate was obtained by lysing in 1x RIPA buffer (Millipore). Membranes were developed using ECL reagent (Immobilon, Millipore). Post primary antibody blotting, membranes were striped, rinsed, and reprobed with the respective internal control antibodies and imaged. Antibodies used in the study is listed in Supplementary Table 2.
Colony formation assay. After 72 h of selection a total of 10 × 10 2 shScr and shSNAI2 cells were seeded in 6-well plates with 2 mL of DMEM (10% FBS). Medium was refreshed every 2 days, and after 14 days, cells were fixed and stained with Diff-Quik® (Medion Diagnostic AG460.053) as per manufacturer's instruction. Colonies containing >50 cells were counted. Triplicate assays were carried out in three independent experiments.
Soft agar colony formation assay. After 72 h of selection a total of 10 × 10 3 shScr and shSNAI2 cells were suspended in DMEM (10% FBS) containing 0.35% agar (NuSieve-GTG-Agarose). Cells were seeded on a layer of 0.7% agar in DMEM (10% FBS) in 6-well plates. Media was refreshed every 2 days. On week 4, colonies were counted by microscopic inspection. Colony numbers were normalized by dividing the number of colonies by the number of total units (colonies + single cells). Triplicate assays were carried out in three independent experiments.
Sphere formation assay. Serially diluted RD, JR1, or SMS-CTR cells were resuspended in 100 μL Neuro Basal Medium (NBM) 44 . The diluted cells were gently added to 1 mL of pre-warmed NBM per well of a 24-well plate (Corning Cat#3603). The cells were incubated for at least 10-12 days with 100 μL of fresh media added every 2 days. The spheres were counted manually or using the Celigo Imaging Cytometer automated cell counting apparatus (Nexcelom Bioscience LLC, Lawrence, MA, USA).
Clinical specimens. Primary samples were obtained from the Pathology Unit of Bambino Gesù Children's Hospital (Rome, Italy) and Department of Pathology, University of Washington (Seattle, WA, USA) and the approval of the study was obtained from the ethics committees at the two Research Centers. Written informed consent was obtained from all patients.
Immunohistochemistry. Immunohistochemistry was performed on 2 µm-thick sections obtained from formalin-fixed tissue embedded in paraffin. After dewaxing and rehydrating, heat-induced epitope retrieval was performed by boiling the slides with EDTA (pH 9) (Dako, Glostrup, Denmark). Endogenous peroxidase was blocked with 3% hydrogen peroxide followed by incubation with mouse-to-mouse blocking reagent to inhibit endogenous mouse immunoglobulin and then another blocking with blocked BSA 5%. Sections were incubated overnight at +4°C with mouse monoclonal α-MF20 antibody (dilution 1:50; DSHB) or rabbit monoclonal α-SNAI2 (dilution 1:100). Detection of the primary antibody was performed by using the appropriate secondary biotinylated antibody (Dako, Carpinteria, USA) and the peroxidase DAB kit (Dako, Carpinteria, USA) with or without counterstaining with Gill's hematoxylin (Dako, Carpinteria, USA). Negative controls were stained in parallel with either isotype non-specific IgG or only the primary antibody. The light microscopy imaging was performed on a Nikon E600 light microscope equipped with NIS Elements BR software, using 20x objective.
RNA-seq. RNA was extracted using the RNeasy mini kit (Qiagen). Poly-A selected RNA libraries were prepared and sequenced on Illumina HiSeq2000. QC was performed using FastQC version 0.11.2 and Picard's version 1.127 RNASeqMetrics function with the default parameters. PCR duplicates were marked using Picard's MarkDuplicates function. RNA-seq reads were aligned to the UCSC hg19 reference genome using TopHat version 2.0.13. Significance was defined as having FDR q = <0.01 and FWER p ≤ 0.05. Gene set enrichment analysis (http://www. broadinstitute.org/gsea/index.jsp) was performed using default parameter settings.
ChIP-seq libraries were prepared using Illumina TruSeqChIP Library Prep Kit (Illumina). Libraries were multiplexed and sequenced using the NextSeq500 (Illumina). Reads were mapped to reference genome (version hg19) using BWA 45 . High-confidence ChIP-seq peaks were called by MACS2.1 46 . Peaks from ChIP-seq of MYOD and H3K27ac were selected at a stringent p ≤ 0.0000000001, while a less restrictive p ≤ 0.000001 was applied to SNAI2. Gene ontology was performed using GREAT, using hg19 and the whole genome as the background. Chromatin states were characterized using ChromHMM (http://compbio.mit.edu/ChromHMM/). Enhancers were identified using the ROSE2 (https://github.com/linlabbcm/rose2) software. Differential peak calling was performed using BEDTools v2.25.0 in multicov mode to measure read counts, which were normalized per million mapped reads, and visualized using R package ggplot2 or NGS plot. Enhancer regions were linked to their nearest gene, irrespective of strand specificity and gene direction, within topologically associated domain (TAD) boundaries using EDEN. Enrichment of known and de novo motifs were found using HOMER. Enrichment peaks were visualized with epigenome browser 47 and IGV 48 . Raw sequencing data and processed files are available (GEO GSE137168).
HiChIP. SMS-CTR cells were fixed with DSG for 10 min at room temperature (23°C), then 1% formaldehyde for 12 min at room temperature. Cells (~8 million) were then lysed gently to release nuclei, permeabilized in 0.5% SDS for 10 min at 62°C, quenched with 10% Triton X-100, and digested with DpnII (400 U, overnight at 37°C) which was then heat inactivated (20 min, 62°C). Biotin incorporation was done with biotin-14-dATP (Thermo, Cat# 19524-016) and DNA Polymerase I, Large (Klenow) Fragment (NEB, Cat# M0210) for 1 h at 37°C. Then we performed in situ ligation with T4 DNA ligase (2 h room temperature and 16°C overnight). Nuclei were pelleted and sonicated (28 cycles with shearing 'on' time with 30 s 'on' 30 s 'off', using the Active Motif Epi-shear probe sonicator, 30% power). Lysates were immunoprecipitated with anti-H3K27ac (Active Motif, Cat# 39133), overnight incubation (rotating at 4°C), then bound to Dynabeads Protein A (Thermo, Cat# 10002D) and incubated (2 h at 4°C). Dynabeads were then held magnetically, washed, eluted, treated with Proteinase K (30 min at 55°C); crosslinks were reversed by heating to 67°C for 2 h. DNA was purified using ChIP DNA Clean & Concentrator kit (Zymo Cat# D5205). Biotin capture and washing was done with Dynabeads M-280 Streptavidin (Thermo, Cat# 11205D), followed by end repair, A-tailing, adapter ligation, and library amplification all on-bead as previously reported 49 . Libraries were paired-end sequenced to a shallow depth of 80-120 million reads. Two independent biological replicates for SMS-CTR were combined informatically to get contact maps with 30 million valid, long-range cis contacts. Analysis was performed using HiC-Pro 50 and visualized in Juicebox 51 .
Re-ChIP. SMS-CTR cells were fixed and sonicated as with ChIP-seq experiments. The first ChIP was performed with MYOD antibody (sc, Catalogue #760) and incubated with sheared chromatin, protease inhibitor cocktail, and Protein G magnetic beads (Active Motif Re-ChIP-IT kit) at 4°C overnight. Magnetic beads were washed, and chromatin was eluted and desalted according to manufacturer's instructions. LSV Protein Magnetic beads were used for the second ChIP reaction, employing SNAI2 antibody (CST, Catalogue #9585). In the same way, the reverse sequence was also performed (first ChIP SNAI2, then MYOD). DNA eluted was purified, and qRT-PCR was performed on ABI QuantStudio6 Real-Time PCR system. List of PCR primers used in this study is listed in Supplementary Table 2. Enrichment of DNA was quantified by the standard curve method.
Quantification and statistical analysis. The significance of results was assessed by applicable statistical tests for each experiment described. Except where stated all experiments were performed at least in three biological replicates. Student's twotailed t-test was used for testing significance of qRT-PCR, sphere assays, colony assays, soft agar assays, and immunohistochemistry staining values and exact p values were reported on the related figures or in the text. Murine experimental data was tested using 2-way ANOVA or two-tailed t-test, a minimum of three mice was used per condition. Representative imaging data from three biological replicates was used to quantify immunofluorescence staining data and significance was assessed by Student's two-tailed t-test and exact p values were reported on the related figures or in the text. Statistical analysis of NGS data was performed as per the analysis program default parameters or else as described in the NGS section. Software used for statistical tests include R, Graphpad Prism, and Microsoft Excel.
Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The datasets generated during this study (RNA-seq, ChIP-seq, and Hi-seq) are available at GEO (Gene Expression Omnibus) with the following accession number (GSE137168). Previously published GEO datasets used in the study were: ChIP-seq in human myoblasts and myotubes (GSE29611, GSE50413), ChIP-seq in RMS and ChIP-seq and RNA-seq in Fibroblasts and Fibroblasts + PAX3-FOXO1 (GSE83728), RNA-seq in Fibroblasts and Fibroblasts + MYOD1 (GSE93263), Hi-C in IMR90 (GSE63525), ChIP-seq and RNA-seq in SMS-CTR ± Trametinib (GSE85171). The remaining data are available within the article, supplementary Information or available from the authors upon request.